Business
Mesoblast shares savaged on poor COVID trial results – Sydney Morning Herald
The stem cell treatment hopeful plunged 41 per cent at the open after revealing its COVID research was unlikely to meet its goals.
The company, will complete the study, which had been aiming to recruit 300 patients, using the 223 patients already enrolled.
Its the second piece of tough news for Mesoblast, which is backed by high profile investors including billionaire Alex Waislitz, to be released this week, after phase 3 trial results of its heart failure drug caused the stock to plunge at the start of the week. The company released data on Tuesday showing its other product, Revascor, showed reduction in mortality of up to…
-
Noosa News9 hours agoShocking moment Bradley Donald Towle arrested after Bruce Hwy rampage and shooting on Sunshine coast
-
Noosa News16 hours agoMollie O’Callaghan admits to doubts, wins gold at Australian Open Swimming Championships
-
General10 hours agoNSW Police to provide update on Sydney woman’s kidnap from Bankstown home and killing
-
General23 hours agoFounder Schwab quits as World Economic Forum chair